RxDoctor Payments Data

Jacinda Chan

Medical · Sacramento, CANPI 1588265854

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (49.4%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Galderma Laboratories, L.p. at 35.4% of the total. 2025 is the largest year on record at $19,358, more than ten times the $1,514 reported in 2022. Among medical clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$30,689in general payments, 2019–2025

Across 548 payments — averaging $56.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Galderma Laboratories, L.p.$11K
  • Incyte Corporation$4K
  • AbbVie$3K
  • Sun Pharmaceutical Industries Inc.$2K
  • UCB, Inc.$2K
  • E.r. Squibb & Sons, L.L.C.$2K
  • plus $8K from 24 others

What the payments were for

  • Consulting fees$5,18217%
  • Speaking & faculty fees$9,37531%
  • Travel & lodging$2751%
  • Food & beverage$15,17549%
  • Education$6822%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$30,689 in reported general payments places this provider in the 95th percentile of 2,087 medical providers in California.

See all medical providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab54$205,079
OpzeluraRuxolitinib Phosphate43$82,131
Taltz AutoinjectorIxekizumab11$71,972
SotyktuDeucravacitinib11$67,371
JubliaEfinaconazole23$33,437
ZoryveRoflumilast21$16,981
Tacrolimus55$12,927
Betamethasone Dipropionate155$9,248
Clobetasol Propionate93$4,861
Ketoconazole257$4,364
Fluocinonide96$2,956
Triamcinolone Acetonide172$1,877
Clindamycin Phosphate43$1,640
Ciclopirox28$1,271
Doxycycline Monohydrate29$852

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationOpzelura$3,576$82,13143 claims
E.r. Squibb & Sons, L.L.C.Sotyktu$1,694$67,37111 claims
Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia$85$33,43723 claims
Arcutis Biotherapeutics, Inc.Zoryve$1,445$16,98121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,087 medical providers in California.

Other medical in Sacramento

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →